Welcome to our dedicated page for Regentis Biomaterials SEC filings (Ticker: RGNT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Regentis Biomaterials Ltd. (RGNT) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including current reports on Form 6-K and registration materials related to its NYSE American listing. As a foreign private issuer, Regentis uses Form 6-K to furnish press releases and other information that it makes public in its home market or files with other regulators.
Recent 6-K filings incorporate press releases on clinical and scientific developments for GelrinC, the company’s lead cell-free, off-the-shelf hydrogel implant for focal articular knee cartilage injuries. For example, a 6-K furnishes the press release titled “Regentis’ GelrinC Establishes Long-Term Durability of Cartilage Repair Through Quantitative MOCART Evaluation,” summarizing Phase II data published in the journal Cartilage and describing MRI-based MOCART scores at 24 months. Another 6-K includes the press release “Regentis Biomaterials Granted New U.S. Patent for its Off-the-Shelf Regenerative Cartilage Repair Product GelrinC,” outlining patent protection for the liquid, ready-to-use formulation and solvent-free production processes.
Filings also cover corporate and governance events, such as changes in executive leadership, and provide formal notice of these developments under the Exchange Act. In addition, the company’s registration statement on Form F-1 and related documents detail its initial public offering of ordinary shares and listing on the NYSE American under the symbol RGNT.
On Stock Titan, these SEC documents are updated as they are made available through EDGAR. AI-powered tools can help readers quickly understand the key points in each filing, such as clinical endpoints, regulatory milestones, intellectual property disclosures, and changes in management, without needing to parse every page manually.
Regentis Biomaterials Ltd. reported that a group of related investors led by Dr. Ehud Geller holds a significant stake in its Ordinary Shares. The Reporting Persons collectively beneficially own 1,332,867 Ordinary Shares, representing 23.2% of the class as of the measurement date.
This ownership figure includes 465,533 options exercisable into 465,533 Ordinary Shares and 92,821 warrants exercisable into 92,821 Ordinary Shares that are currently exercisable or will become exercisable within 60 days after December 31, 2025. The percentage is based on 5,179,378 Ordinary Shares outstanding as of February 20, 2026, plus the shares underlying these options and warrants.
The group, which includes several Medica III and Poalim Medica limited partnerships in Israel and the Cayman Islands, reports zero sole voting or dispositive power and shared voting and dispositive power over all 1,332,867 shares.
Regentis Biomaterials Ltd. is expanding its European clinical site network to support both its commercial plans and ongoing clinical programs for GelrinC®, its lead knee cartilage repair product. GelrinC® already has CE Mark approval in Europe and is slated for commercial launch there in 2026.
The company is adding new sites in regions including Italy and Eastern Europe to deepen relationships with leading orthopedic surgeons and centers of excellence. GelrinC® is described as an off-the-shelf, 10-minute procedure that has shown sustained pain relief and functional improvement for more than 4 years and is currently in a pivotal U.S. FDA study that has completed over 50% enrollment.
Regentis Biomaterials appointed Ori Gon as Chief Financial Officer and Chief Business Officer, effective immediately. He will oversee commercial and business development activities alongside financial strategy, planning, and reporting.
The company highlights this leadership change as GelrinC®, its cell-free hydrogel implant for knee cartilage repair, moves toward commercial launch in Europe following CE Mark approval and continues a pivotal Phase III FDA trial in the U.S., which has passed 50% enrollment. Clinical data to date suggest a single, roughly 10-minute procedure can provide faster recovery, sustained pain relief, and functional improvement for more than four years. Regentis aims to address an estimated 470,000 annual U.S. cartilage knee repair cases where no off-the-shelf treatment is currently available.
Regentis Biomaterials is expanding its U.S. clinical site network for its pivotal Phase III study of GelrinC, a regenerative hydrogel implant for knee cartilage repair. The new academic and clinical orthopedic centers are intended to accelerate patient enrollment, which has already surpassed 50%, and strengthen data quality for future development and commercialization following the company’s recent IPO.
GelrinC is a cell-free, off-the-shelf, 10-minute procedure implant designed to regenerate damaged cartilage and has CE Mark approval in the European Union. It is being evaluated in a pivotal FDA study aimed at addressing a U.S. market of more than 470,000 cartilage knee repair cases annually, where no off-the-shelf treatment is currently available.
Regentis Biomaterials filed a Form 6-K to share new long-term MRI data from a completed European clinical trial of its GelrinC® implant for focal knee cartilage defects. Advanced MRI analysis published in the journal Cartilage showed that, by 24 months after treatment, GelrinC®-treated defects were filled with cartilage displaying a layered internal structure similar to healthy hyaline cartilage, which is considered the gold standard for durable joint function.
The imaging was performed using validated methods accepted by the U.S. FDA and EMA and led by Prof. Siegfried Trattnig’s group, recognized experts in cartilage MRI. Regentis states that these findings support the view that GelrinC® promotes true biological cartilage regeneration rather than fibrotic or scar-like repair, reinforcing its ongoing Phase III FDA study and commercialization efforts in Europe, where GelrinC® already has CE Mark approval.
Regentis Biomaterials Ltd. submitted a Form 6-K as a foreign private issuer, providing investors with access to a new company press release. The filing furnishes a press release titled “Regentis’ GelrinC Establishes Long-Term Durability of Cartilage Repair Through Quantitative MOCART Evaluation,” which discusses long-term durability results for its GelrinC cartilage repair product using quantitative MOCART imaging assessment. The press release is attached as Exhibit 99.1 and incorporated by reference.
Regentis Biomaterials Ltd. reported a leadership change following the resignation of Chief Executive Officer Dr. Eli Hazum, effective December 31, 2025. The company states that Dr. Hazum resigned for personal reasons and that his decision was not due to any disagreement with the company.
On the same day, the board appointed its Chairman, Dr. Ehud Geller, as the new Chief Executive Officer. This means the roles of Chairman and CEO are now held by the same person, which may influence how the company’s strategy and governance are managed going forward.
Regentis Biomaterials Ltd. filed a Form 6-K as a foreign private issuer with the U.S. Securities and Exchange Commission. The report furnishes a press release dated December 18, 2025, titled “Regentis Biomaterials Granted New U.S. Patent for its Off-the-Shelf Regenerative Cartilage Repair Product GelrinC.”
The core update is the disclosure of this new U.S. patent related to GelrinC, which is described as an off-the-shelf regenerative cartilage repair product.